EVOLVE: Evaluation of Oedema and Lymphatic Function following Volumetric Modulated Arc Therapy for Non-melanoma Extensive Skin Field Cancerisation of the Lower Limbs

Cancer Care Research Pty Limited0 个研究点目标入组 10 人开始时间: 2021年11月29日最近更新: 2022年11月21日

适应症

试验速览

暂无简介。

•1.Be aged 50 years or older
•2.Have symptomatic extensive skin field cancerisation (ESFC) greater than 50cm2
•3.Be undergoing wide field (>50cm2), VMAT radiation therapy to the lower limb at
•GenesisCare trial sites in NSW.
•4.Understand and have provide written informed consent for participation in this trial.

•1.Have received prior VMAT wide field radiotherapy (>50cm2 ) to either leg.
•2.History of lymphoedema in either lower limb
•3.Lower limb peripheral vascular intervention prior to radiation therapy
•4.Cardiac pacemaker or Implantable Cardioverter Defibrillator (ICD)
•5.Allergy to shellfish or iodine
•6.Any other condition/factor as defined by the investigator which significantly impact the
•patient’s involvement and suitability in this study

发起方

Cancer Care Research Pty Limited